Amylyx Pharmaceuticals prices 14.09M shares to fund operations, with proceeds totaling $500.2M before expenses.
Amylyx Pharmaceuticals priced an upsized public offering of 14.09 million common shares at $35.50 per share, raising gross proceeds of $500.2 million. The offering is expected to close on or around August 21, 2026, pending customary conditions.
The company previously indicated plans to use proceeds for general corporate purposes, including research and development. No prior comparable offering was disclosed in recent filings. The stock price reflects a premium to recent trading levels, aligning with market demand.
Shares of AMLX showed muted reaction in after-hours trading, as investors await further details on fund allocation.